Anna Vassall

7.9k citations

189 papers · 4.1k indexed · 1 hit paper · h-index 35

Impact in

Infectious Diseases top 0.5%
- Tuberculosis Research and Epidemiology
- HIV/AIDS Research and Interventions
Epidemiology top 1%
- Pneumonia and Respiratory Infections
- HIV, Drug Use, Sexual Risk
- Pneumocystis jirovecii pneumonia detection and treatment

Papers in ⓘ

Infectious Diseases 99
- Tuberculosis Research and Epidemiology 65
- HIV/AIDS Research and Interventions 30
Finance 45
- Healthcare Systems and Reforms 44

Co-authors: Sedona Sweeney (35 shared papers)Edina Sinanovic (13 shared papers)Gavin Churchyard (15 shared papers)Richard G. White (14 shared papers)Nicola Foster (11 shared papers)Gabriela B. Gomez (27 shared papers)Yoko V. Laurence (12 shared papers)Ulla Griffiths (4 shared papers)
Journals: The International Journal of Tuberculosis and Lung Disease (18 papers)PLoS ONE (16 papers)Health Policy and Planning (11 papers)Social Science & Medicine (9 papers)PLoS Medicine (7 papers)
Partner nations: United Kingdom South Africa United States

In The Last Decade

Anna Vassall

179 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

The impact of COVID-19 on TB: a review of the data 2021 · 179 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 The International Journal of Tuberculosis and Lung Disease

Peers

Countries citing papers authored by Anna Vassall

Since Specialization

Citations

This map shows the geographic impact of Anna Vassall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Vassall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Vassall more than expected).

Fields of papers citing papers by Anna Vassall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Vassall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Vassall. The network helps show where Anna Vassall may publish in the future.

Co-authors

The 25 scholars most cited alongside Anna Vassall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anna Vassall Line = papers co-authored together Anna Vassall links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 189 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis PLoS Medicine ·Anna Vassall, Sanne van Kampen, Hojoon Sohn, Joy S. Michael, K. R. John, Saskia den Boon, J. Lucian Davis, Andrew Whitelaw, Mark P. Nicol, Maria Tarcela Gler, Anar Khaliqov, Carlos Zamudio, Mark D. Perkins, Catharina Boehme, Frank Cobelens	2011	250
2	The impact of COVID-19 on TB: a review of the data The International Journal of Tuberculosis and Lung Disease ·Christopher Finn McQuaid, Anna Vassall, Ted Cohen, Kathy Fiekert, COVID TB Modelling Working Group, Richard G. White Hit paper breakdown →	2021	179
3	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF The Lancet Global Health ·Gavin Churchyard, Wendy Stevens, L D Mametja, Kerrigan McCarthy, Violet Chihota, Mark P. Nicol, Linda Erasmus, Norbert Ndjeka, Lindiwe Mvusi, Anna Vassall, Edina Sinanovic, Helen Cox, Christopher Dye, Alison D. Grant, Katherine Fielding	2015	162
4	The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies PLoS Medicine ·Gabriela B. Gomez, Annick Bórquez, Kelsey K. Case, Ana Wheelock, Anna Vassall, Catherine Hankins	2013	161
5	Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries Proceedings of the National Academy of Sciences ·Gwenan M. Knight, Ulla Griffiths, Tom Sumner, Yoko V. Laurence, Adrian Gheorghe, Anna Vassall, Philippe Glaziou, Richard G. White	2014	125
6	Reference case for estimating the costs of global health services and Interventions LSHTM Research Online (London School of Hygiene and Tropical Medicine) ·Anna Vassall, Sedona Sweeney, Jim Kahn, Gabriela Gomez Guillen, Lori Bollinger, Elliot Marseille, Ben Herzel, Willyanne DeCormier Plosky, Lucy Cunnama, Edina Sinanovic, Sergio Bautista‐Arredondo, Kate Lockwood Harris, Carol Levin	2017	117
7	The economic burden of TB diagnosis and treatment in South Africa Social Science & Medicine ·Nicola Foster, Anna Vassall, Susan Cleary, Lucy Cunnama, Gavin Churchyard, Edina Sinanovic	2015	114
8	Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review PharmacoEconomics ·Yoko V. Laurence, Ulla Griffiths, Anna Vassall	2015	113
9	Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience Sexually Transmitted Infections ·Sedona Sweeney, Carol Dayo Obure, Claudia B. Maier, Robert Greener, Karl L. Dehne, Anna Vassall	2011	109
10	Using Top‐down and Bottom‐up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale Health Economics ·Lucy Cunnama, Edina Sinanovic, Lebogang Ramma, Nicola Foster, Leigh Berrie, Wendy Stevens, Sebaka Molapo, Puleng Marokane, Kerrigan McCarthy, Gavin Churchyard, Anna Vassall	2016	80
11	Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis European Respiratory Journal ·Andrea Pantoja, Christopher Fitzpatrick, Anna Vassall, Karin Weyer, Katherine Floyd	2012	72
12	Valuing the work of unpaid community health workers and exploring the incentives to volunteering in rural Africa Health Policy and Planning ·Frida Kasteng, Stella Settumba, Karin Källander, Anna Vassall, (unknown)	2015	62
13	Feasibility, Yield, and Cost of Active Tuberculosis Case Finding Linked to a Mobile HIV Service in Cape Town, South Africa: A Cross-sectional Study PLoS Medicine ·Katharina Kranzer, Stephen D Lawn, Gesine Meyer‐Rath, Anna Vassall, Eudoxia Raditlhalo, Darshini Govindasamy, Nienke van Schaik, Robin Wood, Linda‐Gail Bekker	2012	61
14	The growing burden of noncommunicable disease among persons living with HIV in Zimbabwe AIDS ·Mikaëla Smit, Jack Olney, Nathan Ford, Marco Vitória, Simon Gregson, Anna Vassall, Timothy B. Hallett	2018	56
15	Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation The Lancet Global Health ·Anna Vassall, Mariana Siapka, Nicola Foster, Lucy Cunnama, Lebogang Ramma, Katherine Fielding, Kerrigan McCarthy, Gavin Churchyard, Alison D. Grant, Edina Sinanovic	2017	55
16	Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries Bulletin of the World Health Organization ·Mariana Siapka, Michelle Remme, Carol Dayo Obure, Claudia B. Maier, Karl L. Dehne, Anna Vassall	2014	50
17	Optimal Triage Test Characteristics to Improve the Cost-Effectiveness of the Xpert MTB/RIF Assay for TB Diagnosis: A Decision Analysis PLoS ONE ·Anna H. van’t Hoog, Frank Cobelens, Anna Vassall, Sanne van Kampen, Susan E. Dorman, David Alland, Jerrold J. Ellner	2013	46
18	Study protocol for the Integra Initiative to assess the benefits and costs of integrating sexual and reproductive health and HIV services in Kenya and Swaziland BMC Public Health ·Charlotte Warren, Susannah Mayhew, Anna Vassall, James Kimani, Kathryn Church, Carol Dayo Obure, Natalie Friend du-Preez, Timothy Abuya, Richard Mutemwa, Manuela Colombini, Isolde Birdthistle, Ian Askew, Charlotte Watts	2012	44
19	Financing Essential HIV Services: A New Economic Agenda PLoS Medicine ·Anna Vassall, Michelle Remme, Charlotte Watts, Timothy B. Hallett, Mariana Siapka, Peter Vickerman, Fern Terris‐Prestholt, Markus Haacker, Lori Heise, Andy Haines, Rifat Atun, Peter Piot	2013	42
20	Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa The International Journal of Tuberculosis and Lung Disease ·Lebogang Ramma, Helen Cox, Lynne Wilkinson, Nicola Foster, Lucy Cunnama, Anna Vassall, Edina Sinanovic	2015	42

About Anna Vassall

Anna Vassall is a scholar working on Infectious Diseases, Finance, Economics and Econometrics, Modeling and Simulation and Pediatrics, Perinatology and Child Health, having authored 189 papers that have together received 4.1k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (65 papers), Global Maternal and Child Health (53 papers), Health Systems, Economic Evaluations, Quality of Life (51 papers), Healthcare Systems and Reforms (44 papers), HIV/AIDS Research and Interventions (30 papers), HIV/AIDS Impact and Responses (23 papers), Pneumonia and Respiratory Infections (20 papers) and Pneumocystis jirovecii pneumonia detection and treatment (19 papers). The work is most often cited by research in Infectious Diseases (2.6k citations), Epidemiology (1.7k citations), Finance (474 citations), Modeling and Simulation (202 citations) and Pediatrics, Perinatology and Child Health (850 citations). Anna Vassall has collaborated with scholars based in United Kingdom, South Africa and United States. Frequent co-authors include Sedona Sweeney, Edina Sinanovic, Gavin Churchyard, Richard G. White, Nicola Foster, Gabriela B. Gomez, Yoko V. Laurence, Ulla Griffiths, Michelle Remme and Lucy Cunnama. Their work appears in journals such as The International Journal of Tuberculosis and Lung Disease, PLoS ONE, Health Policy and Planning, Social Science & Medicine and PLoS Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact